Erratum: Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells (Journal of Biological Chemistry (2014)289 (1639–1648) DOI: 10.1074/jbc.M113.500934);Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells

Journal of Biological Chemistry

Volumn 289, Issue 3, 2014, Pages 1639-1648

  Okon, Imoh S ^a   Coughlan, Kathleen A ^a   Zou, Ming Hui ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; CHEMICAL ACTIVATION; DISEASES; LANTHANUM COMPOUNDS; MOLECULAR BIOLOGY; PHOSPHATASES; PHOSPHORYLATION; TUMORS;

HEPATOCYTE GROWTH FACTOR RECEPTOR; INSULIN-LIKE GROWTH FACTOR-I; PATHOLOGICAL CONDITIONS; PHOSPHATASE ACTIVITY; PROTEIN-TYROSINE PHOSPHATASE; RECEPTOR ACTIVATION; RECEPTOR TYROSINE KINASE; TUMOR PROGRESSIONS;

CELL SIGNALING;

PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; STK11 PROTEIN, HUMAN; VANADIC ACID;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VANADATES;

EID: 84892663850     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.AAC119.010208     Document Type: Erratum

References (45)

1. Roskoski, R. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. BBRC 319, 1-11
2. Gullick, W. J. (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med. Bull. 47, 87-98
3. Sorenson, C. M., and Sheibani N. (2002) Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2 -/- mice. Am. J. Physiol. Renal. Physiol. 282, 442-450
4. Tiganis, T. (2002) Protein Tyrosine Phosphatases: Dephosphorylating the Epidermal Growth Factor Receptor. IUBMB Life 53, 3-14 (Pubitemid 34462468)
5. Shah, U., Sharpless, N. E., and Hayes, D. N. (2008) LKB1 and lung cancer: more than the usual suspects. Cancer Res. 68, 3562-3565
6. Zhang, S., Schafer-Hales, K., Khuri, F. R., Zhou, W., Vertino, P. M., and Marcus, A. I. (2008) The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity. Cancer Res. 68, 740-748 (Pubitemid 351206750)
7. Zhuang, Z. G., Di, G. H., Shen, Z. Z., Ding, J., and Shao, Z. M. (2006) Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol. Cancer Res. 4, 843-849 (Pubitemid 44877014)
8. Contreras, C. M., Gurumurthy, S., Haynie, J. M., Shirley, L. J., Akbay, E. A., Wingo, S. N., Schorge, J. O., Broaddus, R. R., Wong, K. K., Bardeesy, N., and Castrillon, D. H. (2008) Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 68, 759-766 (Pubitemid 351206752)
9. Wingo, S. N., Gallardo, T. D., Akbay, E. A., Liang, M. C., Contreras, C. M., Boren, T., Shimamura, T., Miller, D. S., Sharpless, N. E., Bardeesy, N., Kwiatkowski, D. J., Schorge, J. O., Wong, K. K., and Castrillon, D. H. (2009) Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4, e5137
10. Mahoney, C. L., Choudhury, B., Davies, H., Edkins, S., Greenman, C., Haaften, G. v., Mironenko, T., Santarius, T., Stevens, C., Stratton, M. R., and Futreal, P. A. (2009) LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br. J. Cancer 100, 370-375
11. Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., and Vickery, T. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075
12. Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., Nakamoto, M., Shimizu, E., Minna, J. D., and Yokota, J. (2007) Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26, 5911-5918
13. Nony, P., Gaude, H., Rossel, M., Fournier, L., Rouault, J. P., Billaud, M. (2003) Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular charperones Hsp90/Cdc37. Oncogene 22, 9165-9175 (Pubitemid 38067992)
14. Sanchez-Cespedes, M. (2007) A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 26, 7825-7832 (Pubitemid 350261789)
15. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., De-Pinho, R. A., and Cantley, L. C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99 (Pubitemid 38903165)
16. Rodriguez-Nieto, S., and Sanchez-Cespedes, M. (2009) BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 30, 547-554
17. Ylikorkala, A., Rossi, D. J., Korsisaari, N., Luukko, K., Alitalo, K., Henkemeyer, M., and Mäkelä, T. P. (2001) Vascular Abnormalities and deregulation of VEGF in Lkb1-Deficient Mice. Science 293, 1323-1326 (Pubitemid 32777423)
18. Fan, D., Ma, C., and Zhang, H. (2009) The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim. Biophys. Sin. 41, 97-107
19. Boudeau, J., Baas, A. F., Deak, M., Morrice, N. A., Kieloch, A., Schutkowski, M., Prescott, A. R., Clevers, H. C., and Alessi, D. R. (2003) MO25α/β interact with STRADα/β enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 22, 5102-5114 (Pubitemid 37222030)
20. Boudeau, J., Scott, J. W., Resta, N., Deak, M., Kieloch, A., Komander, D., Hardie, D. G., Prescott, A. R., van Aalten, D. M., and Alessi, D. R. (2004) Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 117, 6365-6375 (Pubitemid 40214563)
21. Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., and Alessi, D. R. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843 (Pubitemid 38418750)
22. Hardie, D. G., Carling, D., and Gamblin, S. J. (2011) AMP-activated protein kinase: also regulated by ADP? Trends Biochem. Sci. 36, 470-477
23. Karuman, P., Gozani, O., Odze, R. D., Zhou, X. C., Zhu, H., Shaw, R., Brien, T. P., Bozzuto, C. D., Ooi, D., Cantley, L. C., and Yuan, J. (2001) The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol. Cell 7, 1307-1319 (Pubitemid 32607363)
24. Xie, Z., Dong, Y., Zhang, J., Scholz, R., Neumann, D., and Zou, M. (2009) Identification of the Serine 307 of LKB1 as a Novel Phosphorylation Site Essential for Its Nucleocytoplasmic Transport and Endothelial Cell Angiogenesis. Mol. Cell Biol. 29, 3582-3596
25. Sordella, R., Bell, D. W., Haber, D. A., Settleman, J. (2004) Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science 305, 1163-1167 (Pubitemid 39100331)
26. Hardie, D. G. (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 744-785
27. Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D., Lahad, J., Jacob-Hirsch, J., Amariglio, N., Vaisman, N., Segal, E., Rechavi, G., Alon, U., Mills, G. B., Domany, E., and Yarden, Y. (2007) A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 39, 503-512 (Pubitemid 46514770)
28. Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M. C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., and Wong, K. K. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-811
29. Ostman, A., Frijhoff J., Sandin, A., and Böhmer, F. D. (2011) Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem. 150, 345-356
30. Meng, T. C., Lou, Y. W., Chen, Y. Y., Hsu, S. F., and Huang, Y. F. (2006) Cys-oxidation of protein tyrosine phosphatases: its role in regulation of signal transduction and its involvement in human cancers. J. Cancer Mol. 2, 9-16
31. Cardaci, S., Filomeni, G., and Ciriolo, M. R. (2012) Redox implications of AMPK-mediated signal transduction beyond energetic clues. J. Cell Sci. 125, 2115-2125
32. Emerling, B. M., Weinberg, F., Snyder, C., Burgess, Z., Mutlu, G. M., Viollet, B., Budinger, G. R., and Chandel, N. S. (2009) Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic. Biol. Med. 46, 1386-1391
33. Poels, J., Spasić, M. R., Callaerts, P., and Norga, K. K. (2009) Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. Bioessays 31, 944-952
34. Piantadosi, C. A. (2012) Regulation of mitochondrial process by protein S-nitrosylation. Biochim. Biophys. Acta 1820, 712-721
35. Tennant, D. A., Durán, R. V., and Gottlieb, E. (2010) Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277
36. Trachootham, D., Alexandre, J., and Huang, P. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591
37. Waterman, H., and Yarden, Y. (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142-152 (Pubitemid 32171933)
38. Puri, N., and Salgia, R. (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J. Carcinog. 7, 9
39. Kinch, M. S., Moore, M. B., and Harpole, D. H., Jr. (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 9, 613-618 (Pubitemid 36182592)
40. Faoro, L., Singleton, P. A., Cervantes, G. M., Lennon, F. E., Choong, N. W., Kanteti, R., Ferguson, B. D., Husain, A. N., Tretiakova, M. S., Ramnath, N., Vokes, E. E., and Salgia, R. (2010) EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J. Biol. Chem. 285, 18575-18585
41. Ju, Y. S., Lee, W. C., Shin, J. Y., Lee, S., Bleazard, T., Won, J. K., Kim, Y. T., Kim, J. I., Kang, J. H., and Seo, J. S. (2012) A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22, 436-445
42. Finn, A. J., Feng, G., and Pendergast, A. M. (2003) Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. Nat. Neurosci. 6, 717-723
43. Fernández, A. M., Kim, J. K., Yakar, S., Dupont, J., Hernandez-Sanchez, C., Castle, A. L., Filmore, J., Shulman, G. I., and Le Roith, D. (2001) Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15, 1926-1934 (Pubitemid 32738622)
44. Nitert, M. D., Chisalita, S. I., Olsson, K., Bornfeldt, K. E., and Arnqvist, H. J. (2005) IGF-I/insulin hybrid receptors in human endothelial cells. Mol. Cell. Endocrinol. 229, 31-37 (Pubitemid 40018080)
45. Varewijck, A. J., Yki-Järvinen, H., Schmidt, R., Tennagels, N., and Janssen, J. A. (2013) Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling. Diabetes 62, 2539-2544